Pediapharm Launches EpiCeram(R)

MONTREAL, QUEBEC--(Marketwire - December 07, 2009) - Pediapharm Inc., is announcing the launch of EpiCeram®, a novel skin barrier emulsion indicated for atopic dermatitis and other dry skin conditions. Earlier this year, Pediapharm had announced an agreement with Ceragenix Pharmaceuticals for the Canadian rights to the product.

Atopic dermatitis is a chronically relapsing skin condition that affects mostly children and gives rise to itching and severely dry skin. The disease appears in early childhood, and many patients experience periodic flare-ups throughout adulthood. The prevalence of atopic dermatitis in Canada is estimated to be close to 10% for children less than 14 years old while the burden of the disease has been estimated to exceed 1.2B$ annually in Canada.

EpiCeram® is based on scientific advances in the understanding of the skin barrier and its role in the pathogenesis of atopic dermatitis. EpiCeram® specifically addresses the defective skin barrier of atopic patients by providing a UNIQUE and optimal 3:1:1 ratio of ceramides, free fatty acids and cholesterol to help repair the damaged skin barrier and relieve the signs and symptoms of atopic dermatitis.

"We are very excited about the launch of EpiCeram® in Canada," said Steven Porter, Chairman and Chief Executive Officer of Ceragenix. "The Pediapharm team has been terrific partners so far and we share a common vision for the product. We are confident that their commercialization efforts for EpiCeram® will be successful."

"EpiCeram® is a ground-breaking product that caters to a significant unmet medical need in the treatment of atopic dermatitis," said Sylvain Chretien, President and CEO of Pediapharm. "EpiCeram® fits perfectly with our strategic mission to bring the best therapeutic innovations in paediatrics to ensure the wellbeing of Canadian children. The product is now available by prescription in Canada and this is excellent news for the patients suffering from atopic dermatitis."

EpiCeram® is the subject of a recent peer reviewed journal article in the December issue of the Journal of Drugs in Dermatology which reported on the results of a 121 patient multicenter clinical study which found that EpiCeram®, when used as monotherapy, had comparable efficacy to a mid-strength steroid in the treatment of children with moderate to severe atopic dermatitis, after 28 days of treatment. The article can be accessed via http://jddonline.com/articles/article_information/1151.

About EpiCeram®

In September 2009, Health Canada provided clearance to market EpiCeram® Skin Barrier Emulsion, a topical emulsion that utilizes Ceragenix Pharmaceuticals' Barrier Repair Technology. It s to be used to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including atopic dermatitis. EpiCeram Skin Barrier Emulsion helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

About Pediapharm

Pediapharm is the first and only Canadian pharmaceutical company to focus exclusively on the paediatric pharmaceutical market. Pediapharm leverages its commercial expertise in paediatrics by partnering with companies that develop innovative products and wish to launch those products in Canada. In addition, Pediapharm is maximizing the potential of its Canadian partners by implementing an export strategy through its International Business Unit. Whenever possible, partnered products are offered for international distribution in selected markets through our growing network of commercial partners. Pediapharm is headquartered in Montreal, Quebec and is in the process of registering and/or launching many innovative paediatric products. Through its strong network of key opinion leaders, Pediapharm is optimally positioned to identify and meet unmet medical needs in diseases affecting children. For additional information on Pediapharm, please visit www.pedia-pharm.com.

About Ceragenix

Ceragenix Pharmaceuticals, Inc. (OTCBB: CGXP) is a medical device company focused on infectious disease and dermatology. The company has two base technology platforms; Ceragenins™ for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin™ compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin™ technology to formulate Cerashield™ antimicrobial coatings for medical devices. All Ceragenin™ and Cerashield™ products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform for the development of EpiCeram® which is currently being marketed in the United States and Canada under exclusive distribution agreements. For additional information on Ceragenix, please visit www.ceragenix.com.